PNAS mouse experiments have proven that exercise hormones can block the symptoms of Parkinson's disease

Researchers from the Johns Hopkins School of Medicine and the Dana Farber Cancer Institute in Boston have shown that during endurance or aerobic exercise, a hormone secreted in the blood lowers levels of proteins associated with Parkinson's disease and stops exercise problems

Parkinson's disease is a neurological disorder that causes people to lose control of their muscles and movements, and about 1 million people in the United States have the disease

If confirmed in additional laboratory studies and clinical trials, the researchers' study of mice with Parkinson's disease symptoms could pave the way

The researchers' test results were published Aug.

Ted Dawson MD of the Johns Hopkins School of Medicine and Dr.

Endurance exercise has long been found to relieve the symptoms of Parkinson's disease, but the cause is unknown

Over the past decade, other labs have found that exercise can increase levels of iris, and there is interest in

To test the effects of irisin on Parkinson's disease, Dawson and Spiegelman's team started with a research model used by Dawson in which mouse brain cells were designed to spread small, elongated fibers

When α-synuclein aggregates, these aggregates kill dopamine-producing brain cells, a key trigger for

In a laboratory model, the researchers found that iris prevents the accumulation of α-synuclear protein clumps and their associated brain cell death

Next, the team tested the effects

Further studies of brain cells in mice injected with irisin showed that this exercise hormone reduced levels of parkinson's disease-related α synuclein by 50 to 80 percent

"If the utility of iris is confirmed, we can envision it being developed into a genetic or recombinant protein therapy

"Given that iris is a naturally occurring peptide hormone that appears to have evolved to be able to cross the blood-brain barrier, we believe it is necessary to continue to evaluate iris as a potential treatment for Parkinson's disease and other forms of neurodegenerative degeneration

Dawson and Spiegelman have filed a patent

Original:

Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin